



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PINK1 siRNA (h): sc-44598

BACKGROUND

A member of the serine/threonine protein kinase family, PTEN induced putative kinase 1 (PINK1) is a tumor suppressor. PINK1 is primarily located in mitochondria, and is ubiquitously expressed in testis, skeletal muscle, and heart tissue. It can also be detected at lower levels in pancreas, ovary, brain, placenta, kidney, liver, prostate and small intestine. During cellular stress PINK1 protects against mitochondrial dysfunction by inducing phosphorylation mitochondrial proteins. PINK1 mutations may give rise to different autophosphorylation activity. Mutations in the PINK1 gene (PARK6) are associated with early onset Parkinson's disease, a recessive neurodegenerative disorder characterized by resting tremor, muscular rigidity, bradykinesia and postural instability. Parkinson's disease generally involves the presence of intraneuronal accumulations of aggregated proteins (Lewy bodies) in brain neurons.

REFERENCES

- Unoki, M., et al. 2001. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. *Oncogene* 20: 4457-4465.
- Rogaeva, E., et al. 2004. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. *Arch. Neurol.* 61: 1898-1904.
- Healy, D.G., et al. 2004. The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism. *Ann. Neurol.* 56: 329-335.
- Hatano, Y., et al. 2004. Novel PINK1 mutations in early-onset parkinsonism. *Ann. Neurol.* 56: 424-427.
- Valente, E.M., et al. 2004. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science* 304: 1158-1160.
- Silvestri, L., et al. 2005. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. *Hum. Mol. Genet.* 14: 3477-3492.
- Fung, H.C., et al. 2006. Analysis of the PINK1 gene in a cohort of patients with sporadic early-onset parkinsonism in Taiwan. *Neurosci. Lett.* 394: 33-36.

CHROMOSOMAL LOCATION

Genetic locus: PINK1 (human) mapping to 1p36.12.

PRODUCT

PINK1 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see PINK1 shRNA Plasmid (h): sc-44598-SH and PINK1 shRNA (h) Lentiviral Particles: sc-44598-V as alternate gene silencing products.

For independent verification of PINK1 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-44598A, sc-44598B and sc-44598C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

PINK1 siRNA (h) is recommended for the inhibition of PINK1 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

PINK1 (38CT20.8.5): sc-517353 is recommended as a control antibody for monitoring of PINK1 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor PINK1 gene expression knockdown using RT-PCR Primer: PINK1 (h)-PR: sc-44598-PR (20 μ l, 481 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

SELECT PRODUCT CITATIONS

- Torii, S., et al. 2015. Involvement of inhibitory PAS domain protein in neuronal cell death in Parkinson's disease. *Cell Death Discov.* 1: 15015.
- Yamashita, K., et al. 2017. High expression of the mitophagy-related protein PINK1 is associated with a poor response to chemotherapy and a poor prognosis for patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. *Ann. Surg. Oncol.* 24: 4025-4032.
- Zhang, J., et al. 2018. Artesunate-induced mitophagy alters cellular redox status. *Redox Biol.* 19: 263-273.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.